Health
Study examines efficacy of Pfizer-BioNTech mRNA COVID-19 vaccine across demographic groups – News-Medical.Net
A new study examines data from Israel’s vaccination campaign to assess the efficacy of the Pfizer-BioNTech mRNA vaccine across different demographics.
Scientists across the world are racing against time to develop effective vaccines for severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) to contain the current coronavirus disease 2019 (COVID-19) pandemic. The phase III trial of the mRNA-based BNT162b2 COVID-19 vaccine showed 95% efficacy in preventing SARS-COV-2 infection. In this randomized placebo-controlled trial, the vaccine was found to be effective 12 days following the first dose. Despite several advantages of a controlled trial,…
-
Noosa News22 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
Noosa News23 hours agoForum responds to urgent homelessness issues in Nambour
-
Business19 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
Business20 hours agoDoes Macquarie rate BHP shares a buy after its FY25 results?